BioXcel Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 74
- Market Cap
- $26.8M
- Introduction
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
Clinical Trials
17
Trial Phases
6 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
- Conditions
- Bipolar DisorderSchizophreniaAgitation,PsychomotorSchizophreniform DisordersSchizo Affective Disorder
- Interventions
- Drug: Sublingual film containing Igalmi
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- BioXcel Therapeutics Inc
- Target Recruit Count
- 23
- Registration Number
- NCT06041646
- Locations
- 🇺🇸
BioXcel Clinical Research Site, Rogers, Arkansas, United States
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- BioXcel Therapeutics Inc
- Target Recruit Count
- 13
- Registration Number
- NCT05665088
- Locations
- 🇺🇸
BioXcel Clinical Research Site, Toms River, New Jersey, United States
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
- Conditions
- Agitation,PsychomotorBipolar I DisorderBipolar II DisorderSchizophreniaSchizoaffective DisorderSchizophreniform Disorders
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- BioXcel Therapeutics Inc
- Target Recruit Count
- 452
- Registration Number
- NCT05658510
- Locations
- 🇺🇸
BioXcel Clinical Research Site 137, Las Vegas, Nevada, United States
🇺🇸BioXcel Clinical Research Site 136, Austin, Texas, United States
🇺🇸BioXcel Clinical Research Site 113, Bellflower, California, United States
Study of BXCL501 In Agitation Associated With Delirium in ICU Patients
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- BioXcel Therapeutics Inc
- Registration Number
- NCT05313386
- Locations
- 🇺🇸
BioXcel Clinical Research Site, Nashville, Tennessee, United States
An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- BioXcel Therapeutics Inc
- Target Recruit Count
- 5
- Registration Number
- NCT05276830
- Locations
- 🇺🇸
Bioxcel Clinical Research Site, Springfield, Massachusetts, United States
🇺🇸BioXcel Clinical Research Site, Toms River, New Jersey, United States
- Prev
- 1
- 2
- 3
- Next
News
Uniquity Bio Appoints Will Kane as CEO to Lead Anti-TSLP Therapy Through Phase III Development
Uniquity Bio has appointed Will Kane as President and CEO to advance solrikitug, a monoclonal antibody targeting TSLP, through completion of three Phase II trials and preparation for Phase III development.
MindMed Appoints Matt Wiley as Chief Commercial Officer to Lead MM120 Launch Strategy
MindMed has appointed Matt Wiley as Chief Commercial Officer to oversee the commercial strategy for MM120 ODT, a potential treatment for generalized anxiety disorder and major depressive disorder.
BioXcel Therapeutics Secures $14M Through Direct Stock Offering to Institutional Investors
BioXcel Therapeutics has entered into a securities purchase agreement with institutional investors, raising $14M through a registered direct offering of common stock and warrants.
FDA Concludes Inspection of BioXcel's TRANQUILITY II Phase 3 Trial Site with VAI Status
The FDA has completed its inspection of BioXcel Therapeutics' TRANQUILITY II Phase 3 trial site, designating it as "Voluntary Action Indicated" and releasing the Establishment Inspection Report.
BioXcel Therapeutics Advances Phase 3 Trials for BXCL501 in Agitation Treatment
BioXcel Therapeutics has initiated the SERENITY At-Home Phase 3 trial evaluating BXCL501 for acute agitation in patients with bipolar disorders or schizophrenia, addressing an estimated 23 million annual episodes.
FDA Approves Rexulti as Breakthrough Treatment for Alzheimer's-Related Agitation
Lundbeck and Otsuka's Rexulti (brexpiprazole) becomes the first FDA-approved medication specifically for treating agitation in Alzheimer's disease patients, affecting approximately 50% of cases.
BioXcel Therapeutics Advances Phase 3 Trials of BXCL501 for Agitation
BioXcel Therapeutics has randomized the first patient in the SERENITY At-Home trial, evaluating BXCL501 for acute agitation associated with bipolar disorders or schizophrenia.
Bioxcel Therapeutics Gains Analyst Confidence with Agitation Treatment Advancements
H.C. Wainwright reiterated a Buy rating for Bioxcel Therapeutics (BTAI), citing the Phase 3 trial of BXCL501 for agitation in bipolar disorder and schizophrenia.